Full text is available at the source.
Prescription de l’olanzapine chez l’enfant et l’adolescent
Aug 7, 2007L'Encephale
Use of Olanzapine in Children and Teenagers with Mental Health Conditions
AI simplified
Abstract
Of the 53 patients aged 6-18 treated with olanzapine for child onset schizophrenia, 27 out of 34 with a first episode were considered responders.
- Olanzapine is associated with significant improvement in treatment-resistant childhood schizophrenia, as shown by a response rate of 68% in that group.
- In adolescent onset schizophrenia, 85% of patients treated with olanzapine were considered responders after 8 to 26 weeks.
- Weight gain is a prominent adverse effect of olanzapine treatment, reportedly greater in children and adolescents than in adults.
- Sedation may affect up to 50% of patients treated with olanzapine, similar to those taking haloperidol.
- Extrapyramidal symptoms are described as mild to moderate, occurring more frequently than in adult patients but less so than with haloperidol.
AI simplified
INTRODUCTION: A review of the literature from 1996-2004 on the indications and adverse reactions concerning the use of olanzapine, a second generation antipsychotic agent, in children and adolescents with psychiatric illness is made in this article. Studies lasted for 2 to 3 months and a few had a follow up period up to a year. Olanzapine, dosed from 2.5 to 20 mg/day, is shown to be a useful drug in the treatment of child and adolescent onset schizophrenia, bipolar disorder, anorexia nervosa with delusions, pervasive developmental disorder, tic disorders, and aggression. OPEN AND DOUBLE-BLIND STUDIES: In 4 open labeled studies (26, 34, 39, 43) and 2 case reports (25), 53 patients, aged from 6-18 years old, afflicted by child onset schizophrenia, were treated with olanzapine for 1 1/2 weeks to one year; 19 had treatment resistant childhood schizophrenia and 34 a first episode. In the first group 13/19 showed improvement whereas, in the second group 27/34 were considered responders. Four patients in the first group who had responded to clozapine (stopped because of adverse events) did less well on olanzapine. In 5 studies, 4 open labeled (15, 20, 44) and 1 double blind (27), 59 adolescent onset schizophrenic patients were treated by olanzapine from 8 to 26 weeks; 50/59 patients were considered responders. In the open label study (20) comparing 43 adolescents treated by olanzapine (19 patients), risperidone (17 patients), or haloperidol (7 patients), improvement was significant in the three groups after 4 weeks of treatment and continued after 8 weeks. It is most interesting to mention that 2 months after the end of the study 71% (12/17) of the olanzapine group that had completed the study, 10/15 (67%) of the risperidone group, and 43% (3/7) of the haloperidol group had continued their treatment. Dropouts were for inefficacy and non-compliance in the olanzapine and risperidone groups whereas they were also for adverse events in the haloperidol group (2/4). A final double blind study of 263 adult and adolescent schizophrenic patients (latter are not separated from the former) confirmed the superiority of olanzapine compared to haloperidol and its use for a long period: 67% of the olanzapine and 54% of the haloperidol patients completed the 12-week study.
CASE-REPORTS: 12 case reports of children and adolescents diagnosed with acute mania (8, 25, 46, 47) and 23 in an open labeled study (16) were treated by olanzapine; 26/35 were considered to respond well. Some of the patients were on mood stabilizers before adjunction of olanzapine, others on olanzapine monotherapy; 10 case reports of patients with anorexia nervosa associated with psychotic symptomatology, aged from 10-17 years old, relate the use of olanzapine as adjuvant treatment. Improvement was spectacular in these patients who not only gained considerable weight, but were also more compliant to the therapeutic program and their obsessions, delusions, agitation and anxiety became less intense. In this form of anorexia nervosa, olanzapine appears to have an interesting therapeutic role and, in particular, its most important adverse effect, weight gain, became a therapeutic goal. In 2 preliminary studies (24, 30) 31 children and adolescents diagnosed with pervasive developmental disorder were treated by olanzapine from 6 to 13 weeks; 18/25 had good or moderate symptomatic improvement: they were less irritable and hyperactive, and their speech less excessive. In 17 case reports of children and adolescents with aggression (42, 45), associated with tics in 10 patients (49), treatment with olanzapine from 2 weeks to 10 months lowered the presenting symptoms, enhanced the cooperation, and improved the mood of the patients. Only one patient's treatment was changed for inefficacy.
DISCUSSION: No matter what the disorder treated, when olanzapine was compared to haloperidol and risperidone, it proved to be as effective as risperidone, and as or more effective than haloperidol; but when compared to clozapine, it was less effective. The most prominent adverse reaction was excessive weight gain, even more so than in adult patients treated with olanzapine. Also weight gain was greater in children and adolescents treated by olanzapine than those treated by risperidone or haloperidol. Though few treatments had to be interrupted because of this side effect, child and adolescent psychiatrists are wary of the long-term disease related to obesity and glucose dysregulation. All should be done to under-stand the process of weight gain better and to prevent or stall excessive caloric intake, encourage activity, and eventually treat by corrector drugs. Secondly, sedation may bother up to 50% of patients even at the end of the study periods, as many as those treated by haloperidol and more than those treated by risperidone. Extrapyramidal symptoms were mild or moderate compared to those that appear with haloperidol, but may be more frequent than in adult patients. Liver enzymes and blood sugar may be slightly elevated. Prolactemia may be elevated but less so with risperidone and haloperidol.
CONCLUSION: All the authors emphasized the unfortunate lack of randomized double blind studies for the use of olanzapine in this age group.
Related papers
Jan '05
Use of Antipsychotic Medications in Bipolar Disorder
top 50% journal
cited by 26 papers
journal article
Jun '05
Cost-effectiveness of long-acting injectable atypical antipsychotics in care settings for people with schizophrenia
top 50% journal
cited by 37 papers
journal article
Oct '03
Short-term comparison of risperidone, olanzapine, and haloperidol in treating psychosis in young people
cited by 260 papers
randomized controlled trial
Nov '06
Comparing haloperidol, risperidone, and olanzapine for early treatment of first-time nonaffective psychosis
top 10% journal
cited by 137 papers
randomized controlled trial
Feb '01
Olanzapine's use in treating schizophrenia: an updated review
cited by 171 papers
journal article
Sep '08
Comparing older and newer antipsychotic drugs in young people with early schizophrenia and related disorders
top 1% journal
cited by 385 papers
randomized controlled trial
Jun '22
Average Cost of Antipsychotic Drugs Used in Turkey in 2020
journal article
Jul '10
Metabolic side effects of risperidone in early-onset schizophrenia
top 50% journal
cited by 17 papers
journal article
Dec '07
Metabolic changes over 12 weeks in first-episode psychosis patients untreated before, treated with haloperidol, olanzapine, or risperidone
top 10% journal
cited by 76 papers
randomized controlled trial
Sep '02
Use and prescribing patterns of four uncommon antipsychotic drugs at Charles Perrens Psychiatric Hospital (Bordeaux)
top 50% journal
cited by 4 papers
comparative study